Business Context and Reporting Period
This Form 8-K was filed by pSivida Corp. on February 3, 2011. The report discloses a material event regarding the clinical development of the company's product, Iluvien, which is licensed to Alimera Sciences, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a clinical milestone rather than financial performance data.
Material Changes
The primary material event is the announcement of Month 36 top-line results from the Phase 3 FAME Study of Iluvien in patients with diabetic macular edema. These results were reported by pSivida's licensee, Alimera Sciences, Inc.
Guidance, Outlook, and Risks
Management commentary is limited to the issuance of a press release and the filing of webcast slides detailing the clinical study results. The filing does not contain updated financial guidance, specific risk factors, or contingencies beyond the disclosure of the clinical data readout.
Investor Verification Checklist
- Review the full text of the press release filed as Exhibit 99.1 for specific clinical outcome details.
- Examine the webcast slides filed as Exhibit 99.2 for the complete Month 36 data from the FAME Study.
- Verify the commercial implications of the Phase 3 results for the Iluvien license agreement with Alimera Sciences.